The 1st clinical research of BI-505 accomplished our goals. The candidate medication was well tolerated and indicated therapeutic effect, since seven of a complete of 29 individuals with advanced multiple myeloma demonstrated steady disease for at least 8 weeks. The beginning of this stage II research is another essential step of progress for BI-505 and we think that BI-505 gets the potential to address a significant unmet want in a wide population of patients. .. BioInvent starts BI-505 phase II research in sufferers with smoldering multiple myeloma BioInvent International announced today that the 1st patient offers been treated in a stage II research of the drug applicant BI-505, developed for the treating multiple myeloma.Natural wellness allies in the mainstream are few in number, and Norris is among a few that truly grasp medical freedom conditions that we write about at NaturalNews on a regular basis. In a recently available column at WorldNetDaily, Norris explains to readers why we must all band and combat as one to protect our health freedoms together, which are quickly disappearing right before our eyes. Citing the near-total dominance in the US of GMO staple crops like corn, soy, and canola, Norris paints a grim picture of the sizable beast we presently face.